research use only

Sodium nitroprusside

Name: Sodium nitroprusside
Brand: Selleck Chemicals
SKU: S4493
Availability: InStock
Rating: 5 (3 reviews)

Cat.No.S4493

Sodium nitroprusside (SNP, Ro 21-2498) is a generically available and rapid-acting intravenous (IV) vasodilator that dilates cerebral vessels and increases internal carotid (ICA) flow.

Chemical Structure

Molecular Weight: 261.92

Jump to

Quality Control

Batch: Purity: 99.93%

99.93

Related Targets	PROTAC Dyes Antineoplastic and Immunosuppressive Antibiotics ADC Cytotoxin Selection Antibiotics for Transfected Cell Antibiotics for Mammalian Cell Culture ADC Linker Molecular Glues Hydrotropic Agents Antibiotics for Plant Cell Culture
Other Others Inhibitors	Furimazine (PBI 3939) BAY 2927088（Sevabertinib） Guanidinoacetic acid BAPTA-AM Blebbistatin Polybrene (Hexadimethrine Bromide) Silibinin (NSC 651520) Carbazochrome sodium sulfonate (AC-17) Palmitic acid Osthole

Solubility

In vitro
Batch:

DMSO : 52 mg/mL (198.53 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 52 mg/mL

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	261.92	Formula	C₅FeN₆O^.2Na	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	14402-89-2	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	SNP, Ro 21-2498			Smiles	[Na+].[Na+].[Fe++](\|[C-]#N)(\|[C-]#N)(\|[C-]#N)(\|[C-]#N)(\|[C-]#N)\|N#[O+]

Mechanism of Action

References	[1] https://pubmed.ncbi.nlm.nih.gov/29917239/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01199250	Not yet recruiting	Lynch Syndrome\|Recurrent Uterine Corpus Carcinoma\|Stage I Uterine Corpus Cancer\|Stage II Uterine Corpus Cancer\|Stage III Uterine Corpus Cancer\|Stage IV Uterine Corpus Cancer	Gynecologic Oncology Group\|National Cancer Institute (NCI)\|GOG Foundation	January 2100	--
NCT06405945	Recruiting	Cervical Cancer Susceptible Population Classification	Anhui Provincial Hospital	May 1 2024	--
NCT05987956	Not yet recruiting	Non-small Cell Lung Cancer	Han Xu M.D. Ph.D. FAPCR Sponsor-Investigator IRB Chair\|Medicine Invention Design Inc	March 8 2024	Phase 2\|Phase 3
NCT06062810	Not yet recruiting	Non-Small Cell Lung Cancer	Han Xu M.D. Ph.D. FAPCR Sponsor-Investigator IRB Chair\|Medicine Invention Design Inc	March 28 2024	Phase 2\|Phase 3
NCT06265623	Not yet recruiting	Chronic Obstructive Pulmonary Disease (COPD)	Universitätsklinikum Hamburg-Eppendorf	March 1 2024	--

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):